Androgen receptor signaling contributes to targeted therapy resistance in melanoma
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers have shown. The findings provide a new target to combat therapeutic resistance and one possible answer to why men face a poorer prognosis than women when diagnosed with melanoma.
Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.
Source link aaaaa